Injectable MK-677 — known in research circles as MK677 INJ — represents a distinct delivery approach to one of the most-studied growth hormone secretagogues in modern peptide research. Unlike its oral counterpart, the injectable format bypasses first-pass hepatic metabolism, offering researchers an alternative administration route for investigating ibutamoren’s dose-dependent effects on GH and IGF-1 signaling. This overview compiles the current body of evidence and what the research community has observed.
What Is MK677 INJ?
MK-677 (ibutamoren) is a non-peptide, orally active spiropiperidine compound that acts as a potent, selective agonist of the ghrelin receptor (GHSR-1a). Originally developed by Merck in the early 1990s, it was designed to stimulate pulsatile growth hormone secretion and downstream IGF-1 production without the off-target glucocorticoid activity that plagued earlier GH secretagogues. The injectable formulation delivers the same mechanism through subcutaneous or intramuscular administration, potentially modifying the pharmacokinetic profile and bioavailability relative to oral dosing. With a plasma half-life of approximately 24 hours, MK-677 supports once-daily dosing regardless of route.
Research Overview
MK-677 has accumulated one of the more robust preclinical and clinical research records among growth hormone secretagogues. A landmark 1996 study published in The New England Journal of Medicine by Chapman et al. demonstrated that MK-677 significantly elevated GH and IGF-1 levels across both young and older adult populations, with effects sustained over two months of administration (PubMed: 8937461). Subsequent work by Murphy et al. (2001) examined cognitive and sleep architecture outcomes in older adults, noting improvements in REM sleep stages alongside the hormonal changes (PubMed: 11349101). A two-year placebo-controlled trial by Nass et al. (2008) evaluated MK-677 in GH-deficient adults and reported improvements in lean body mass and bone mineral density (PubMed: 18270265). Google Scholar hosts an extensive secondary literature on GH secretagogue receptor pharmacology that researchers in this space will find relevant.
Community Discussion
The peptide research community has maintained active discussion of MK-677, particularly around the injectable formulation versus oral administration. The r/Peptides subreddit (reddit.com/r/Peptides) hosts ongoing threads comparing pharmacokinetics, injection site tolerability, and observed IGF-1 response differentials between routes. A recurring theme is that researchers using the injectable format report faster onset and more consistent plasma levels, though controlled head-to-head studies remain limited in the public literature. Community consensus generally points to subcutaneous administration in the abdominal region as the most common approach used in informal research settings.
Potential Benefits Studied
- Increased GH and IGF-1 secretion: Multiple human trials confirm dose-dependent elevation of pulsatile growth hormone release and circulating IGF-1 levels lasting the duration of administration.
- Lean body mass preservation: Research in catabolic and GH-deficient populations shows statistically significant improvements in fat-free mass over 8–24 week study windows.
- Bone mineral density: Extended studies in elderly and GH-deficient subjects document increases in bone turnover markers and cortical bone density with chronic MK-677 administration.
- Sleep architecture: Early research suggests improvements in REM sleep duration and slow-wave sleep, consistent with GH’s known role in sleep regulation.
- Appetite and metabolic signaling: As a ghrelin mimetic, MK-677 reliably increases appetite — a property being studied in the context of anorexia, cachexia, and muscle-wasting conditions.
- Wound healing and recovery: Preclinical data and anecdotal research reports suggest accelerated tissue repair pathways downstream of elevated IGF-1, though human trial data in this area remains sparse.
Dosage & Administration
Published clinical trials have administered MK-677 in doses ranging from 10 mg to 25 mg per day, with the 25 mg dose producing the most pronounced GH and IGF-1 response in the Chapman et al. and Nass et al. studies. For injectable formulations, subcutaneous administration is the standard approach — researchers typically reconstitute or use pre-mixed solutions and inject into the abdominal subcutaneous tissue. Due to the 24-hour half-life, once-daily administration is generally sufficient to maintain steady-state plasma levels. Research protocols have extended from 8 weeks to 24 months without reporting significant tachyphylaxis, though insulin sensitivity and fasting glucose should be monitored in extended investigations given MK-677’s effect on insulin-like signaling pathways.
Where to Find It
Researchers sourcing injectable MK-677 for laboratory investigation can find this compound available at combatresearch.is. Combat Research supplies research-grade compounds intended strictly for in vitro and research use.
Conclusion
MK677 INJ occupies a well-studied position in GH secretagogue research, with a literature base spanning nearly three decades and touching on lean mass, bone density, sleep, and metabolic function. The injectable administration route adds a pharmacokinetic variable that remains underexplored in controlled trials, making it an area of active interest for researchers who have already characterized the oral formulation. As with any investigational compound, methodical documentation, baseline biomarkers, and periodic IGF-1 and glucose monitoring are recommended throughout any research protocol.
Disclaimer: This article is intended for educational and research purposes only. MK-677 is not approved by the FDA for human therapeutic use. All compounds referenced on combatresearch.is are sold strictly for research and laboratory use. This content does not constitute medical advice. Consult a licensed healthcare provider before using any compound.
